Niels H Andersen1, Kristian A Groth2, Agnethe Berglund3,4, Hanne Hove5,6, Claus H Gravholt7,4, Kirstine Stochholm7,8. 1. Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. dr.holmark@gmail.com. 2. Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. 3. Department of Clinical Genetics, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200, Aarhus, Denmark. 4. Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200, Aarhus, Denmark. 5. Center for Rare Diseases, Department of Pediatrics, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen , Denmark. 6. The RAREDIS Database, Section of Rare Diseases, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen, Denmark. 7. Department of Endocrinology, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200, Aarhus, Denmark. 8. Center for Rare Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200, Aarhus, Denmark.
Abstract
OBJECTIVES: Studies indicate that other cardiovascular problems than aortic disease are a burden for patients with Marfan syndrome (MFS). The aim of the study was to assess the extent of this issue. METHODS: A registry-based population study of patients with a Ghent II verified MFS diagnosis. Each patient was matched with up to 100 controls on age and sex. From the Danish healthcare system, we identified 407 MFS patients (from 1977 to 2014) and their cardiovascular events and compared them with those in 40,700 controls. Total follow-up time was 16,439 person years. RESULTS: Mitral valve disease was significantly more common in MFS [HR: 58.9 (CI 38.1-91.1)] and happened earlier and more often in women than men with MFS [age at first registration: 22 vs. 38 years, HR: 2.1 (CI 1.0-4.4)]. Heart failure/cardiomyopathy was also more common in MFS [HR: 8.7 (CI 5.7-13.4)] and men were more affected than women, and at younger age [39 vs. 64 years, HR: 0.18 (CI 0.06-0.55)]. In all cases, atrioventricular block [HR: 4.9 (1.5-15.6)] was related to heart surgery. Supraventricular [HR: 9.7 (CI 7.5-12.7)] and ventricular tachycardia [HR: 7.7 (CI 4.2-14.3)] also occurred more often than in the control group. The risk of sudden cardiac death was increased [HR: 8.3 (CI 3.8-18.0)] but the etiology was unclear due to lack of autopsies. CONCLUSION: Non-aortic cardiovascular disease in patients with MFS is exceptionally prevalent and the range of diseases varies between women and men. Physicians caring for MFS patients must be aware of this large spectrum of cardiovascular diseases.
OBJECTIVES: Studies indicate that other cardiovascular problems than aortic disease are a burden for patients with Marfan syndrome (MFS). The aim of the study was to assess the extent of this issue. METHODS: A registry-based population study of patients with a Ghent II verified MFS diagnosis. Each patient was matched with up to 100 controls on age and sex. From the Danish healthcare system, we identified 407 MFSpatients (from 1977 to 2014) and their cardiovascular events and compared them with those in 40,700 controls. Total follow-up time was 16,439 person years. RESULTS:Mitral valve disease was significantly more common in MFS [HR: 58.9 (CI 38.1-91.1)] and happened earlier and more often in women than men with MFS [age at first registration: 22 vs. 38 years, HR: 2.1 (CI 1.0-4.4)]. Heart failure/cardiomyopathy was also more common in MFS [HR: 8.7 (CI 5.7-13.4)] and men were more affected than women, and at younger age [39 vs. 64 years, HR: 0.18 (CI 0.06-0.55)]. In all cases, atrioventricular block [HR: 4.9 (1.5-15.6)] was related to heart surgery. Supraventricular [HR: 9.7 (CI 7.5-12.7)] and ventricular tachycardia [HR: 7.7 (CI 4.2-14.3)] also occurred more often than in the control group. The risk of sudden cardiac death was increased [HR: 8.3 (CI 3.8-18.0)] but the etiology was unclear due to lack of autopsies. CONCLUSION:Non-aortic cardiovascular disease in patients with MFS is exceptionally prevalent and the range of diseases varies between women and men. Physicians caring for MFSpatients must be aware of this large spectrum of cardiovascular diseases.
Authors: H C Dietz; G R Cutting; R E Pyeritz; C L Maslen; L Y Sakai; G M Corson; E G Puffenberger; A Hamosh; E J Nanthakumar; S M Curristin Journal: Nature Date: 1991-07-25 Impact factor: 49.962
Authors: Benjamin N Schaeffer; Meike Rybczynski; Sara Sheikhzadeh; Ruken Ö Akbulak; Julia Moser; Mario Jularic; Doreen Schreiber; Anne Daubmann; Stephan Willems; Yskert von Kodolitsch; Boris A Hoffmann Journal: Clin Res Cardiol Date: 2015-06-02 Impact factor: 5.460
Authors: Bart L Loeys; Harry C Dietz; Alan C Braverman; Bert L Callewaert; Julie De Backer; Richard B Devereux; Yvonne Hilhorst-Hofstee; Guillaume Jondeau; Laurence Faivre; Dianna M Milewicz; Reed E Pyeritz; Paul D Sponseller; Paul Wordsworth; Anne M De Paepe Journal: J Med Genet Date: 2010-07 Impact factor: 6.318
Authors: Kristian A Groth; Kirstine Stochholm; Hanne Hove; Kasper Kyhl; Pernille A Gregersen; Niels Vejlstrup; John R Østergaard; Claus H Gravholt; Niels H Andersen Journal: Clin Res Cardiol Date: 2016-08-22 Impact factor: 5.460
Authors: Simon Winther; Lynne K Williams; Michelle Keir; Kim A Connelly; Timothy J Bradley; Harry Rakowski; Andrew M Crean Journal: J Comput Assist Tomogr Date: 2019 May/Jun Impact factor: 1.826
Authors: Meike Rybczynski; Thomas S Mir; Sara Sheikhzadeh; Alexander M J Bernhardt; Claudia Schad; Hendrik Treede; Simon Veldhoen; Eike F Groene; Kristin Kühne; Dietmar Koschyk; Peter N Robinson; Jürgen Berger; Hermann Reichenspurner; Thomas Meinertz; Yskert von Kodolitsch Journal: Am J Cardiol Date: 2010-10-01 Impact factor: 2.778
Authors: Kristian A Groth; Kirstine Stochholm; Hanne Hove; Niels H Andersen; Claus H Gravholt Journal: Am J Cardiol Date: 2018-07-21 Impact factor: 2.778
Authors: Jennifer Thomson; Mukti Singh; Alexander Eckersley; Stuart A Cain; Michael J Sherratt; Clair Baldock Journal: Semin Cell Dev Biol Date: 2018-07-20 Impact factor: 7.727